News
AFMD
0.6964
+1.09%
0.0075
SVB Securities Remains a Buy on Affimed (AFMD)
TipRanks · 1d ago
Stifel Maintains Hold on Affimed, Lowers Price Target to $1
Benzinga · 4d ago
Stifel Adjusts Price Target on Affimed to $1 From $2, Maintains Hold Rating
Stifel Adjusts Price Target on Affimed to $1 From $2, Maintains Hold Rating
MT Newswires · 5d ago
H.C. Wainwright Sticks to Its Buy Rating for Affimed (AFMD)
TipRanks · 5d ago
Affimed Files For Common Stock Offering Of Up To $100M
Benzinga · 5d ago
BRIEF-Affimed NV Files For Common Stock Offering Of Up To $100 Million - SEC Filing
Reuters · 5d ago
Affimed hits new 52-week low after Q4 2022 results
Seeking Alpha · 5d ago
Earnings Scheduled For March 23, 2023
Benzinga · 6d ago
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 6d ago
BRIEF-Affimed Reports 2022 Financial Results And Operational Progress
Reuters · 6d ago
Affimed GAAP EPS of -€0.60, revenue of €41.35M
Seeking Alpha · 6d ago
Affimed FY 2022 Earnings Preview
Seeking Alpha · 6d ago
Notable earnings before Thursday's open
Seeking Alpha · 6d ago
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/16 11:55
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/14 12:15
AbCheck develops microfluidics tech for antibody discovery under Czech grant pact
Seeking Alpha · 03/09 10:55
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/01 00:15
SVB Securities Keeps Their Buy Rating on Affimed (AFMD)
TipRanks · 02/22 16:26
AbCheck teams up to use microfluidics tech to discover antibodies for neurological disorder
Seeking Alpha · 02/21 10:44
Affimed Shifts Attention To Risky Combination Therapy With NK Cells For T-Cell Lymphoma
Seeking Alpha · 02/17 19:02
More
Webull provides a variety of real-time AFMD stock news. You can receive the latest news about Affimed through multiple platforms. This information may help you make smarter investment decisions.
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.